RxDoctor Payments Data

Adam Amos, MD

Family Medicine · Greencastle, INNPI 1407122666

Payments from drug & device makers

$693in general payments, 2019–2025

Across 43 payments — averaging $16.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$176
  • Novo Nordisk$148
  • GSK$77
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$54
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$52
  • Novartis$42
  • plus $143 from 7 others

What the payments were for

  • Food & beverage$693100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$693 in reported general payments places this provider in the 55th percentile of 2,709 family medicine providers in Indiana.

See all family medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$2,896
Medicare patients
18
Services billed
42

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin100$109,016
EliquisApixaban90$79,507
MounjaroTirzepatide66$79,438
JanuviaSitagliptin Phosphate54$59,677
OzempicSemaglutide24$39,381
FarxigaDapagliflozin Propanediol36$33,014
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$24,750
VraylarCariprazine Hcl15$20,436
WegovySemaglutide12$15,289
XareltoRivaroxaban18$14,868
TradjentaLinagliptin19$14,516
LinzessLinaclotide20$14,459
Stiolto RespimatTiotropium Br/Olodaterol Hcl17$12,814
TrulicityDulaglutide13$12,810
Breo ElliptaFluticasone/Vilanterol20$11,242

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$18$92,24879 claims
Novo NordiskOzempic, Wegovy$148$54,67036 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$77$42,76553 claims
AstraZenecaFarxiga, Symbicort$13$40,60356 claims
AbbVieVraylar, Linzess, Synthroid$176$37,87298 claims
Johnson & JohnsonXarelto$40$14,86818 claims
Astellas Pharma US IncMyrbetriq$18$7,56014 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$12$2,490283 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 2,709 family medicine providers in Indiana.

Other family medicine in Greencastle

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →